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repertoires of CBP to chromatin
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Multiple signaling pathways ultimately modulate the epigenetic information embedded in the chromatin of gene
promoters by recruiting epigenetic enzymes. We found that, in estrogen-regulated gene programming, the
acetyltransferase CREB-binding protein (CBP) is specifically and exclusively methylated by the coactivator-
associated arginine methyltransferase (CARM1) in vivo. CARM1-dependent CBP methylation and p160 coac-
tivators were required for estrogen-induced recruitment to chromatin targets. Notably, methylation increased the
histone acetyltransferase (HAT) activity of CBP and stimulated its autoacetylation. Comparative genome-wide
chromatin immunoprecipitation sequencing (ChIP-seq) studies revealed a variety of patterns by which p160, CBP,
and methyl-CBP (meCBP) are recruited (or not) by estrogen to chromatin targets. Moreover, significant target
gene-specific variation in the recruitment of (1) the p160 RAC3 protein, (2) the fraction of a given meCBP species
within the total CBP, and (3) the relative recruitment of different meCBP species suggests the existence of a target
gene-specific ‘‘fingerprint’’ for coregulator recruitment. Crossing ChIP-seq and transcriptomics profiles revealed
the existence of meCBP ‘‘hubs’’ within the network of estrogen-regulated genes. Together, our data provide
evidence for an unprecedented mechanism by which CARM1-dependent CBP methylation results in gene-
selective association of estrogen-recruited meCBP species with different HAT activities and specifies distinct
target gene hubs, thus diversifying estrogen receptor programming.
[Keywords: CREB-binding protein; CARM1/PRMT4; arginine methylation; estrogen signaling; genome-wide binding
sites; gene networks]
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Nuclear hormone receptors (NRs) are ligand-activated
transcription factors (TFs) that bind to cognate DNA re-
sponse elements of target genes. They control gene ex-
pression by recruiting a repertoire of multicomponent
enzymatic machineries to remodel the chromatin struc-
ture and assemble the transcriptional machinery. In the
absence of ligands, some NRs are located in the nucleus,
bind to the DNA response elements of target genes, and
recruit corepressor complexes that contain histone deacet-
ylases, which induce a repressive chromatin state at the
target locus. The NR subfamily of steroid hormone re-
ceptors, unless exposed to certain antagonists, does not
generally recruit corepressor complexes. Instead, these
NRs are either located in the cytoplasm and/or kept inac-
tive by chaperones. Yet, for all NRs, agonist binding trig-
gers a common principle; namely, allosteric changes that
lead to the exposure of receptor surface(s) for interaction
with coactivators and dissociation of corepressors from the
nonsteroid NRs. While a plethora of NR coactivators has
been described, most of the structure–function studies have
been done with the paradigmatic p160/SRC family (compris-
ing SRC1/NCoA1, SRC2/TIF2/GRIP-1/NCoA2, and SRC3/
RAC3/pCIP/AIB1/ACTR/TRAM/NCoA3) (Gronemeyer
et al. 2004; Rosenfeld et al. 2006; Gronemeyer and
Bourguet 2009; York and O’Malley 2010). The SRC coac-
tivators provide, in turn, a scaffold for tethering secondary
coactivators such as coactivator-associated arginine meth-
yltransferase 1 (CARM1/PRMT4) and CREB-binding pro-
tein (CBP) to target genes. CARM1/PRMT4 (hereafter
referred to as CARM1) belongs to the family of protein
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arginine methyltransferases of type I that catalyzes the
formation of asymmetric dimethylarginine (Bedford and
Clarke 2009). CARM1 was first identified in a yeast two-
hybrid screen for proteins interactingwith the p160 steroid
coactivator GRIP1/TIF2 and was shown to interact with
the activation domain 2 of all three p160 family members.
CARM1 cooperates with the acetyltransferase CBP when
recruited by p160 proteins via their activation domain 1
(for review, see DY Lee et al. 2005). Thus, p160 proteins
constitute a platform for the formation of a multicompo-
nent complex that contains distinct histone-modifying
enzymatic activities: CBP is known to activate transcrip-
tion by acetylating histone tails on specific lysine residues,
whereas CARM1 methylates histone H3 on Arg 17 and
Arg 26, which correlates with NR-mediated gene activa-
tion (Ma et al. 2001; Daujat et al. 2002).
Arginine methylation is not restricted to post-trans-
lational modification of histones. CARM1 also methyl-
ates a variety of nonhistone proteins (Bedford and Clarke
2009), including coactivators such as CBP/p300 (Xu et al.
2001; Chevillard-Briet et al. 2002; YH Lee et al. 2005) and
p160 family members (Feng et al. 2006; Naeem et al.
2007). Different domains of CBP and p300 can be meth-
ylated by CARM1 in vitro. Methylation within the KIX
domain of p300 abrogates its interaction with CREB (Xu
et al. 2001), while methylation of CBP in a region further
downstream has no influence on CREB signaling but is
important for estrogen receptor (ER)-dependent transcrip-
tion (Chevillard-Briet et al. 2002). Notably, methylation
of p300 in this region is required for response to DNA
damage (Lee et al. 2011). Finally, methylation of p300
within the p160 interaction domain (GBD, for GRIP-
binding domain) has been proposed to disrupt the p300/
p160 complex in vitro (YH Lee et al. 2005).
In the present study, we investigated the role of CBP
methylation by CARM1 for ligand-induced CBP recruit-
ment to ER-responsive target genes. Comparative genome-
wide chromatin immunoprecipitation sequencing (ChIP-
seq) showed the existence of distinct but overlapping binding
site repertoires specific for each methyl-CBP (meCBP) spe-
cies, suggesting that CBP methylation by CARM1 specifies
estrogen-induced subprograms.
Results
Site-specific methylation of CBP by CARM1 in vivo
Both CBP and p300 are substrates for CARM1 that
methylate six arginines in CBP/p300 in vitro (Fig. 1A; Xu
et al. 2001; Chevillard-Briet et al. 2002; YHLee et al. 2005).
Transient transactivation assays were performed in estro-
gen-dependentH3396 breast cancer cells in the presence of
a methylation-deficient pointmutation of a single (R714K,
R742K, and R768K) or two arginine (R2104/2151K) resi-
dues that correspond to the methylation site identified in
p300 in the GBD (R2142) and to a site that is important for
the activity of the p300–GRIP1 complex (Xu et al. 2001;
Chevillard-Briet et al. 2002; YH Lee et al. 2005). These
experiments revealed that CBP-mediated superactivation
of an estrogen response element (ERE)-driven luciferase
reporter required the integrity of the histone acetyltrans-
ferase (HAT) domain and all CARM1 target sites, with the
exception of those in the KIX domain (Fig. 1B). To demon-
strate that CARM1 methylates CBP and p300 not only in
vitro but also in vivo, we generated monospecific poly-
clonal antibodies that recognize selectively the CARM1-
methylated epitope encompassing CBP arginines required
for estrogen-dependent transcription (CBPR714me2a,
CBPR742me2a, CBPR768me2a, and CBPR2151me2a) or the
epitope comprising nonmethylated R2151 (CBPR2151non-me)
by ELISA (Supplemental Material); the antibodies were
validated by Western blotting of recombinant in vitro
methylated or nonmethylated CBP (Fig. 1C). Immunopre-
cipitations of endogenous CBP fromH3396 cells with anti-
meCBP antibodies, followed by immunoblot analysis with
the general A22 anti-CBP antibody, demonstrated that
CBP is methylated on these residues in vivo (Fig. 1D, left
panel). Knockdown of CBP by RNAi obliterated immuno-
detection of all methyl-selective antibodies, thus confirm-
ing that they recognized CBP epitopes. Analysis of mouse
embryo fibroblasts (MEFs) lacking CARM1 (Yadav et al.
2003) demonstrated that CARM1 is the only enzyme that
methylates CBP on these residues in vivo and confirmed
antibody selectivity. Indeed, no meCBP was immunopre-
cipitated from CARM1/ MEFs using antibodies specific
for the various asymmetrically dimethylated arginines,
while CBP was readily detected with the identical anti-
bodies in immunoprecipitations from CARM1+/+ MEFs
(Fig. 1D, right panel). While CBP nonmethylated at R2151
(CBPR2151non-me) was detected in CARM1
/ MEFs, no
such species was observed in CARM1+/+ or H3396 cells,
which confirms the antibody selectivity for nonmeth-
ylated R2151. CBPR2151non-me was also absent in MCF7,
LnCaP, HCT116, and several other cells (Fig. 1E; data not
shown). Thus, in cells expressing functional CARM1,
CBPR2151 is mainly, if not exclusively, methylated.
CBP methylation increases its HAT activity
and its autoacetylation
The acetyltransferase (HAT) activity of CBP is important
for coactivation and phosphorylation can modulate its
enzyme activity and substrate specificity (Ait-Si-Ali et al.
1998; Huang et al. 2007). To test whether methylation
regulates its HAT activity, CBP was immunoprecipitated
from CARM1/ and CARM1+/+ MEFs, and HAT assays
were performed with a histone H3 peptide as a substrate.
Interestingly, the HAT activity of CBP from CARM1/
MEFs was markedly decreased relative to that from wild-
type MEFs (Fig. 1F), indicating that CARM1-dependent
CBP methylation increases its HATactivity. As autoacet-
ylation regulates HAT activity of p300/CBP (Thompson
et al. 2004; Black et al. 2006; Arif et al. 2007), we tested
whether methylation regulates CBP HAT activity by
altering autoacetylation. Indeed, Western blots with an
antibody recognizing autoacetylated CBP in immunopre-
cipitations from CARM1+/+ or CARM1/MEFs revealed
that, relative to total CBP, the fraction of autoacetylated
CBP was strongly increased when CARM1 was expressed
(Fig. 1G). That the same CARM1+/+ MEFs also display
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a largely enhanced HAT activity of CBP (Fig. 1F) supports
amechanism bywhichmethylation by CARM1 increases
CBP autoacetylation, which in turn enhances its HAT
activity.
To analyze whether specific methylation sites were
involved in modulating HATactivity, antibodies recogniz-
ing CBP methylated selectively at R742, R768, or R2151
were used to immunoprecipitate CBP that was modified
on these sites in H3396 cells in vivo. Notably, methylation
at R768—and, to a lesser extent, R742—increases HAT
activity as compared with global CBP (Fig. 1H). Not
surprisingly, methylation at R2151 did not have any im-
pact on HAT activity relative to global CBP, as our study
indicates that most, if not all, CBP is methylated at this
site. Finally, immunoprecipitation of the various methyl
species used for HAT assays that were immunoblotted in
parallel for CBP autoacetylation showed a direct correla-
tion between CBP HAT activity and autoacetylation (Fig.
1I). Immunoprecipitations of H3396 cells transfected with
either wild-type or mutant CBPs further supported that
each CBP methylation site is required for efficient HAT
activity. The mutations R742K and R2104K/R2151K—and,
Figure 1. CBP is exclusively methylated
by CARM1 in vivo and methylation in-
creases its HAT activity. (A) CBP methyla-
tion sites identified in vitro. (CH1-3) Zinc
fingers 1–3; (Br) bromodomain. (B) Tran-
sient transactivation assays of an estrogen-
responsive luciferase reporter in H3396
breast cancer cells transfected with 100 ng
or 1 mg of CBP or its methylation-deficient
mutants. (C) Recombinant CBP fragments
nonmethylated or methylated in vitro by
CARM1 were detected by immunoblotting
with the antibodies recognizing the meCBP/
non-meCBP species as indicated. (D) Im-
munoprecipitations of H3396 nucleofected
with siRNAs against CBP or control siRNA
(left panel) or of CARM1/ and CARM1+/+
extracts (right panel) with the indicated
antibodies followed by immunoblotting
with the general CBP-A22 antibody. (E)
MCF7, LnCaP, and HCT116 nuclear ex-
tracts were immunoprecipitated with the
indicated antibodies, and precipitated pro-
teins were analyzed by immunoblot with
CBP-A22 antibody. (F,G) Immunoprecipita-
tions of extracts from CARM1/ and
CARM1+/+MEFswithCBP (A22) or a control
antibody. (Top panel) Different amounts of
the identical immunoprecipitation were
subjected in parallel to HAT assays using
histone H3 peptide as a substrate, and to
immunoblotting with CBP A22 or an anti-
body recognizing autoacetylated CBP. (Bot-
tom panel) CBP amounts were quantified
using ImageJ, and graphs were from at least
three independent experiments. (H,I) Im-
munoprecipitations of H3396 cell extracts
with CBP (A22) and antibodies recognizing
CBPR742me2a, CBPR768me2a, and CBPR2151me2a
or a control antibody. Immunoprecipitations
were subjected in parallel to HATassays and
to immunoblotting with CBP (A22) or an
antibody recognizing CBP autoacetylation,
and quantifications were as in F and G. (J)
Immunoprecipitations with an anti-HA an-
tibody of H3396 cell extracts transfected
with HA-CBP wild type or HA-CBPmutated
on R742, R768, or R2104/2151 into lysines
were subjected to immunoblotting with
antibodies recognizing CBP autoacetylation, CBPR742me2a, CBPR768me2a, and CBPR2151me2a and quantifications relative to CBP wild type
were as in F and G. Statistically significant differences are shown: (*) P < 0.01; (**) P < 0.001; (***) P < 0.001.
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to a lesser extent, R768K—impaired CBP autoacetylation,
revealing that the integrity of these residues is important
for CBP HAT activity (Fig. 1J, left panel, note that similar
results were obtained with the single CBPR2151K mutant).
Interestingly, immunoblotting the same immunoprecipi-
tations with antibodies recognizing CBP methylated se-
lectively at R742, R768, or R2151 revealed a cross-talk
between these sites. Indeed,mutations R742K andR2151K
strongly affected reciprocal methylation, while R768K
decreased methylation at R742 and R2151 moderately
(Fig. 1J). Altogether, our data support a model in which
the methylation and integrity of CBP at R742, R768, and
R2151 stimulate CBP HAT activity by increasing its
autoacetylation.
Methylation and interaction of CBP with p160
proteins are critically required for recruitment
to ERa target genes
The synergy between CARM1 and CBP for steroid hor-
mone receptor coactivation depends on the integrity of
CARM1-dependent CBPmethylation in its central region
(R714, R742, and R768) and in the GBD (R2151) (Fig. 1A,B;
Chen et al. 2000; Chevillard-Briet et al. 2002; YH Lee
et al. 2005). As it has been proposed that methylation of
the p300 GBD plays an important role in NR coactivator
complex assembly (YH Lee et al. 2005), we investigated
whether methylation affects recruitment of CBP to the
prototypic estrogen-responsive TFF1 promoter in H3396
cells, which express high levels of ERa and CBP (Supple-
mental Fig. 1A–C). That estrogen induced the level of
‘‘active’’ chromatin marks at the TFF1 promoter (includ-
ing H3K9ac, CARM1-dependent H3R17me2a, and the re-
cruitment of ERa, TIF2, RAC3, CARM1, CBP, and p300)
(Supplemental Fig. 1D–F) confirmed a functional estrogen
response in H3396 cells.
ChIP analyses demonstrated that estrogen recruited all
methylated CBP species to TFF1 (Fig. 2A). Similar results
were obtained for other ERa target genes (Supplemental
Fig. 2). Competition with the cognate R-methylated but
not the nonmethylated peptides dramatically reduced the
ChIP signals, confirming the selective recognition ofmeCBP
species (Fig. 2A). Re-ChIPs proved that the antibodies
indeed recognized CBP rather than protein(s) harboring
Figure 2. Methylated CBP was recruited to
the TFF1 promoter. (A) H3396 cells, treated
with E2 or vehicle (EtOH) for 1 h, were
subjected to ChIP with the indicated anti-
bodies. Bound DNA was amplified by real-
time PCR with specific primers for TFF1
and GAPDH promoters. For peptide compe-
tition, 100-fold molar excess of either the
corresponding cognate peptide or an irrele-
vant control peptide was added to the anti-
body prior to ChIP. The means 6 standard
deviations are from at least two indepen-
dent experiments. (B) H3396 cells were
subjected to a first ChIP using the general
CBP antibody (A22), and complexes were
eluted and subjected to a second immuno-
precipitation with or without specific anti-
body as indicated. Bound DNA was
amplified as in A. (C) Knockdown of
CBP monitored by RT–PCR (left panel)
and Western blotting (right panel). CBP
mRNA levels are shown relative to those
of 36B4. Immunoblots were done with
A22, and TIF1b was the loading control.
(D) H3396 cells were nucleofected with
siRNAs directed against CBP or a control
siRNA (ctr). After 48 h, cells were treated
with E2 or vehicle (EtOH) for 1 h and
subjected to ChIP with or without the in-
dicated antibodies. Bound DNA was ampli-
fied as in A.
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identical/cross-reacting epitopes (Fig. 2B). Knocking down
CBP in H3396 cells demonstrated that CBP deficiency
alters CBPR2151me2a recruitment, but not that of p300 or
RAC3, and excluded cross-reaction with p300 (Fig. 2C,D).
Identical results were obtained with the other methyl-
selective CBP antibodies, confirming recruitment of all
four methylated CBP species to TFF1 (data not shown). As
expected, CARM1 knockdown decreased total CBP and
meCBP recruitment by estrogen to TFF1 (Fig. 3A,B). No
compensatory recruitment of CBPR2151non-me was seen,
thus providing initial evidence indicating that CBP meth-
ylation is important for binding to TFF1 (see also below).
It is commonly believed that p160 proteins act as
assembly factors for CBP recruitment, but formal proof
was lacking. The collective knockdown of all three p160s
significantly reduced estrogen-dependent binding of global
CBP and CBPR2151me2a to TFF1, revealing unequivocally
their involvement in CBP recruitment (Fig. 3C,D). Coim-
munoprecipitations (co-IPs) with antibodies directed
against global CBP (A22), CBPR742me2a, CBPR768me2a, or
CBPR2151me2a confirmed that CBP methylated at R742,
R768, or R2151 is fully capable of interacting with RAC3
in vivo (data not shown). The above results show CBP
recruitment to TFF1 in a p160 and CARM1-dependent
fashion in vivo. Importantly, co-IPs of transiently expressed
HA-tagged CBPmutants R714K, R742K, or R768K revealed
significantly impaired in vivo RAC3 binding of themutants
and a complete loss of RAC3 binding of CBPR2104K,2151K as
Figure 3. CARM1-dependent methylation
and interaction with p160/SRC coactivators
were required for ligand-induced CBP re-
cruitment to TFF1. (A) H3396 cells were
nucleofected with a siRNA against CARM1
or a control siRNA. After 48 h, cells were
treated with E2 or vehicle for 1 h and ChIP
assays were done with the indicated anti-
bodies. Bound DNA was amplified by real-
time PCRwith specific primers for TFF1 and
GAPDH promoters. The means 6 standard
deviations are from at least two independent
experiments. (B, top) Knockdown of CARM1
monitored by RT–PCR. CARM1 mRNA
levels are displayed relative to 36B4mRNA.
(Bottom panel) Expression of CARM1 was
assessed by immunoblotting. (C) H3396 cells
were nucleofected with a siRNA against
p160 or a control siRNA (ctr). After 48 h,
cells were treated with estrogen (E2) or
vehicle for 1 h and ChIP assays were done
with the indicated antibodies. Bound DNA
was amplified by real-time PCR as in A. (D)
Knockdown of p160s monitored by RT–PCR
and immunoblotting. P160mRNA levels are
displayed relative to 36B4mRNA. (Top right
panel) Expression of RAC3 was assessed by
immunoblotting, and TIF1b was the loading
control. (E) Immunoprecipitations with an
anti-RAC3 antibody of H3396 cell extracts
transfected with HA-CBP wild type or HA-
CBP mutated on R714, R742, R768, or
R2104/2151 into lysines were subjected to
immunoblotting with antibodies recogniz-
ing either RAC3 (top panel) or HA (bottom
panel). Quantifications of RAC3 and HA-
CBP were done relative to the expression in
CBP wild-type condition using ImageJ soft-
ware. (F) H3396 cells stably infected with
retroviral vector expressing HA-CBP wild
type or the methylation-deficient CBP mu-
tants HA-CBPR714K, HA-CBPR742K, HA-
CBPR768K, and HA-CBPR2104/2151K were
treated with E2 or vehicle (EtOH) for 1 h
and subjected to ChIP with an anti-HA
antibody. Bound DNA was amplified by real-time PCR with specific primers for TFF1 and DPP10 promoters; DPP10 was used as
a cold region for ChIP reference. Results are expressed as FO relative to DPP10 relative to ethanol controls. (Bottom panel) Amounts of
expressed HA-CBP and methylation-deficient mutants were determined by immunoblotting with anti-HA antibody.
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compared with the corresponding HA-CBP wild type
(Fig. 3E). Moreover, ChIP experiments performed on
TFF1 and several ER target genes in H3396 cells stably
expressing CBP or CBP methylation-deficient mutants
(R714K, R742K, R768K, and R2104K/2151K) revealed
that CBPwild type but none of themutants was efficiently
recruited to ER target promoters, albeit some residual
recruitment was still observed (Fig. 3F; data not shown).
Together, these results demonstrate that the integrity of
these CARM1-methylated arginines is important for
RAC3 coactivator interaction, and thus for efficient CBP
recruitment to ER target genes.
Genome-wide binding patterns of meCBP species
upon ER activation
Comparative chromatin-binding profiles for ERa, RAC3,
CARM1, CBP and its CARM1-methylated species, global
H3 and H3K18 acetylation (a histone mark that is
catalyzed by CBP and p300), and RNA polymerase II in
the presence and absence of estrogen were established by
ChIP-seq. Peak prediction was performed byMACS using
P-values optimized by receiver operating characteristic
(ROC) curve analyses from the comparison of 68 loci with
the experimentally determined results obtained by ChIP
coupled to real-time PCR (ChIP-qPCR) (see the Supple-
mental Material). A 1-h pulse of estrogen led to a dramatic
nearly 10-fold increase of ERa-binding sites due to de novo
ERa recruitment to nearly 9000 new sites, and resulted
concomitantly in a large increase of loci (>6600) occupied
by CBP (Fig. 4A,B). ChIP-seq profiles were extensively
validated by ChIP-qPCR, as depicted for the loci encom-
passing RAPGEFL1-RARA-IGFBP4, GREB1, or DICER
(Fig. 4C; Supplemental Fig. 3A–C) and a large number of
additional binding sites (Supplemental Material). Compar-
isonwith the ERa cistromemapped inMCF7 (Carroll et al.
2006; Lin et al. 2007; Welboren et al. 2009) revealed a core
of 284 commonly identified sites and 4915 sites found by
at least two groups (Supplemental Fig. 3D). The two groups
using ChIP-seq report 2333 common sites even though
different cell lines (H3396 and MCF7) were used. Note
that, in the present study, the colocalization patterns
apparent from the comparative global mapping of CBP,
its methylated species, ERa, and RAC3 reveal the high
precision of the present binding site analysis and confirm
at the same time the absence of nonmethylated CBPR2151
at a global scale.
That apo-ERa and CBP were detected at 1148 and 534
loci, respectively, implies that, under hormonally naive
conditions, CBP was not strongly engaged by other tran-
scription regulators, at least not to an extent comparable
with its recruitment by holo-ERa (Fig. 4A,B). Interestingly,
estrogen had a rather different effect on the binding char-
acteristics of pre-existing and induced sites. As expected,
the mean number of tags increased for pre-existing sites,
but de novo binding sites displayed, on average, fewer tag
counts, and sites that got lost had the lowest amounts of
tags. In the case of CBP, but not ERa, the average size of
isolated tags increased upon ligand exposure for preoccu-
pied sites. This suggests that preoccupied loci are poised to
respond more rapidly and/or more efficiently to the hor-
monal stimulus. The increased size of CBP-binding sites is
compatible with a model in which holo-ERa initiates local
events that lead to recruitment of additionalCBP-interacting
factors, thereby stabilizing a complex that occupies a larger
region.
Estrogen action induces different patterns of cofactor
binding to target sites
Comparative analysis of ChIP-seq profiles revealed a lo-
cus-specific variability in the recruitment of cofactors by
ERa. For the majority of known ER target genes, ERa
recruitment occurs in a hormone-dependent manner
concomitantly with the binding of coactivator RAC3,
CBP, and its methylated species, resulting in promoter-
proximal histone H3K18 acetylation, while polymerase II-
binding profiles differ only for a few loci (Fig. 4C; Supple-
mental Fig. 3A–C). However, we noted several alternative
binding paradigms. While TFF1 binds efficiently ERa,
RAC3,CBP, and p300, theER-binding fragment-associated
antigen 9 (EBAG9), an estrogen-inducible putative regula-
tor of tumor progression, and CTBP1 bind ERa at the
transcriptional start sites (TSSs) but display weak RAC3
(data not shown) and little if any binding of CBP or p300
(Fig. 4D,E). Despite the apparent absence of these two
HATs, there is a strong peak of locally defined histone H3/4
acetylation and polymerase II binding to the same site, sug-
gesting that ERa recruits a distinct HAT. Another rather
unique example of differential binding between meCBP
species isCARM1, which binds in the presence of estrogen
mainly CBPR742me2a at the TSS and several exonic sites
correlating with peaks of histone H3/4 acetylation (Sup-
plemental Fig. 4A). Another unusual binding paradigmwas
observed at the CBP gene (CREBBP) itself, which bound
ERa and meCBP species, particularly CBPR742me2a, in the
absence of a ligand. Estrogen destabilized (me)CBP binding
but did not affect that of ERa (Supplemental Fig. 4B).
Together, these results reveal that, in contrast to the sim-
plified view according to which holo-ERa recruits coactiva-
tors, which in turn recruit HATs, there is a plethora of
alternative bindingmodes that impact on the efficiency of
recruitment of these factors, most likely reflecting promoter
complexity and chromatin constitution and dynamics.
Estrogen induces distinct binding patterns
of meCBP species
As for CBP, estrogen exposure of H3396 cells resulted in
de novo binding of meCBP species to ERa target sites. A
total of 2249 sites, of which 539 pre-existed, became
occupied by CBPR2151me2a, and 3652 sites were bound by
CBPR768me2a, of which very few pre-existing sites (157)
were seen for this species (Fig. 5A). Not all ERa-binding
sites recruited RAC3 and/or CBP, as 885 sites were co-
occupied by all three factors, while 1013 and 702 sites
were shared solely by ERa and either RAC3 or CBP,
respectively (Fig. 5B). The 90 sites co-occupied by RAC3
and CBP are candidates for ERb-dependent recruitment
or indirectly induced binding. Among the three meCBP
species, all combinations of binding site co-occupancy
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Figure 4. Genome-wide binding patterns of estrogen-recruited ERa and CBP species. (A,B) Venn diagrams and box plots revealing the
numbers of peaks called by MACS from the ChIP-seq experiments for ERa and CBP. Parameters for optimal sensitivity and specificity of
peak detection by MACS version 1.3.7.1 were derived from ROC curves (Supplemental Material). Peak size and overlap analysis was done
with ChordChart. The Venn diagrams display peak numbers detected for the indicated conditions; ‘‘E2’’ indicates 1 h of treatment. The box
plots illustrate the characteristics of peak populations with respect to number of tags or peak base lengths in base pairs. (C, left panel) Signal
peak representation in UCSC (University of California at Santa Cruz) Genome Browser format of ChIP-seq profiles for ERa, CARM1, RAC3,
CBP (A22), and the indicated R-methylated or nonmethylated CBP species after 1 h of estrogen or vehicle exposure. Patterns of histone
H3K18 acetylation and RNA polymerase II binding are shown for comparison. (Right panels) Binding sites near the RAPGEFL1, RARA, and
IGFBP4 genes were validated independently by ChIP-qPCR. (D) Comparative binding site patterns for CBP, ERa, RNA polymerase II,
and H3/4 acetylation at the putative EBAG9 promoter. (E) Kinetics of estrogen-induced binding of ERa, CBP, and p300 to TFF1, EBAG9, and
CTBP1 in H3396 cells treated with E2 or vehicle for the indicated time. Chromatin-immunoprecipitated DNA was amplified by real-time
PCR with binding site-specific primers. The means 6 standard deviations are from at least two independent experiments.
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Figure 5. Differential global estrogen-induced recruitment patterns of methylated CBP species. (A) Venn diagrams displaying pre-
existing and de novo generated chromatin-binding sites in H3396 at global scale for CBPR2151me2a and CBPR768me2a after 1 h of estrogen or
vehicle treatment. (B) Venn diagrams as in A revealing E2-induced recruitment of CBP, ERa, and RAC3 to common and divergent binding
sites. (C) Venn diagram as in B illustrating the recruitment of CBPR768me2a, CBPR2151me2a, and CBPR742me2a to common and divergent
binding sites upon E2 treatment. (D) ChordChart representation of binding patterns for the indicated factors at chromosome 2
(1–40,000,000 bp). The X-axis comprises the cumulative CBP IDs of consecutive peaks along the chromosome. Peaks for the different fac-
tors are represented by weighted dots according to the number of tags generating a peak. Binding sites at GREB1 and LTBP1 are indicated.
(E) Scatter plot (top panel) derived from ChIP-qPCR validations (bottom panel) of E2-induced binding sites identified by ChIP-seq display-
ing FOs (relative to DPP10 site 1) of CBP relative to those of RAC3 at multiple loci, some of which are indicated; only ERa-binding loci
were considered. (F) Scatter plot as in E but revealing divergent FOs of CBP and CBPR768me2a (relative to DPP10 site 1) at E2-induced
ERa-binding sites. (G) Differential recruitment of methylated CBP species to individual ERa target genes. Scatter plot (left panel) derived
from ChIP-qPCR validations (right panels) for E2-induced ERa-binding loci. The scatter plot displays normalized FOs for CBPR2151me2a
relative to CBPR742me2a. FOs for the meCBP species were normalized relative to the FOs of bulk CBP at the same site, thereby taking into
account variations of total CBP binding. Statistically significant differences are shown: (*) P < 0.01; (**) P < 0.001; (***) P < 0.0001.
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were observed with 449 sites commonly occupied by
CBPR742me2a, CBPR768me2a, and CBPR2151me2a (Fig. 5C).
However, between 182 and 408 sites were co-occupied
by only two meCBPs and >1000 sites were bound by only
one of the species. To illustrate the global binding patterns
of the various factors and CBP species, we developed
ChordCharts (Supplemental Material), which can be
weighted according to the binding site-associated P-values
or tag numbers (Fig. 5D). Such ChordCharts visualize site-
selective recruitment and possible divergent functionality/
signaling of these various meCBP species.
To validate the existence of divergent site-specific
binding patterns, we used quadruplicate ChIP-qPCR. Scat-
ter plots of close to 50 binding sites revealed an astounding
heterogeneity. Comparing the DPP10-calibrated fold oc-
cupancies (FOs) at a given site for CBP and RAC3 revealed
a spectrum of relative occupancies in which, for example,
theMAG1 site exhibited a threefold higher occupancy for
RAC3 than the IGFBP4 site (Fig. 5E). Note the statistically
highly significant differences between RAC3 and CBP FOs
forMAG1, PREX1(5), and RARA, while these FOs are not
significantly different for GREB1(3) and IGFBP4. Compar-
ing the FOs of CBP and its R768me2a species revealed
a much higher abundance of CBPR768me2a at IGFBP4 than
at RARA, PREX1(5), and DICER sites (Fig. 5F). Similar
conclusions about the heterogeneity of binding site occu-
pancies can be drawn for the methylated CBP species. To
this end, FOs for CBPR742me2a and CBPR2151me2a were
calibrated relative to those of total CBP; the corresponding
scatter plot reveals very clearly a large spectrum of relative
binding occupancies of the two species for different loci
(Fig. 5G). Together, the above data show an enormous
variability of the relative bindings of different factors (i.e.,
TFs and cognate coregulators) and, moreover, of epigenet-
ically modified HAT cointegrators to ERa target genes.
Different global positioning and divergent HAT
activity of meCBP species at TSS
HATs are enriched at TSSs (Wang et al. 2009). Plotting
binding sites found 10 kb upstream of and downstream
from TSSs (Fig. 6A) revealed a dual peak of ERa: one at
a position where RAC3 andmeCBP species also peak, and
a second one ;100 base pairs (bp) further downstream,
while total TSS-proximal CBP hits the highest point
between the ERa peaks (Fig. 6B). H3/4 acetylation peaks
at the position of the downstream peak of ERa but shows
a shoulder at the TSS position. Comparing promoter
acetylation with the presence of a particular CBP species
revealed major differences (Fig. 6C). While <40% of the
sites bound by CBPR2151me2a also revealed acetylated
histones, >60% of the loci were H3/4-acetylated when
CBPR742me2a was recruited to this site. CBPR768me2a
binding correlated with acetylation of 46% of the bound
sites. While these results revealed a correlation between
the recruitment of a particular meCBP to a given pro-
moter region and the likelihood of that region to be
acetylated, it did not allow a direct correlation between
the extent of acetylation and the binding of a meCBP
species. To obtain this information, the average number of
tags showing H3/4 acetylation was compiled for all species
at a genome-wide level (Fig. 6D). The recruitment of ERa to
a locus even in absence of CBP strongly increased the
acetylation level of that site, and the corecruitment of
ERa and CBP did not significantly change acetylation
levels. This indicates that, in the majority of cases, ERa
binding results in recruitment of aHATother thanCBP, and
that holo-ERa binding without any HAT corecruitment is
the exception. Importantly, however, the average level of
histone acetylation was increased significantly over that
seen at ERa-occupied sites when either CBPR768me2a or
CBPR742me2a was corecruited. These results are fully in line
with the decreased HATactivity of CBP observed in in vitro
assays with CARM1/ cells (Fig. 1F) and the increased
activity found in immunoprecipitations inH3396 cells with
specific antibodies against CBPR768me2a or CBPR742me2a as
compared with total CBP (Fig. 1H). The above data confirm
at a global level that methylation of CBP at R742 and/or
R768 increases its HAT activity in vivo.
In order to further support that the divergent HAT
activities at the most proximal TSSs are due mainly to
differential methylation of CBP and are not mediated by
another HAT, subclones of H3396 cells expressing lenti-
viral shRNAs against CARM1 or CBP to decrease endog-
enous CARM1 and CBP protein levels were generated.
These cell lines were used in ChIP experiments on TFF1
and several other ER target genes with antibodies against
ERa, CBP, CARM1, pan-acetylated histone H3, and
histoneH3 acetylated onK14 or K18, twowell-documented
histone H3 marks that are catalyzed by CBP and p300 in
vivo (Ferrari et al. 2008; Horwitz et al. 2008). Our data
showed that acetylation of histone H3 at K14 and K18 was
strongly decreased in the absence of CBP (shCBP) but also in
the absence of CARM1 (shCARM1) (Fig. 6E; data not
shown), demonstrating that both CBP and CARM1 are
involved in histone H3 acetylation at E2-responsive
promoters and that CBP methylation is directly or
indirectly responsible for the acetylation status of his-
tones on chromatin.
meCBP species specify distinct gene hubs within
the estrogen-regulated gene network
Transcription profiling at 1, 2, 6, and 24 h after estrogen
exposure identified ;1100 genes that were regulated by
estrogen directly or indirectly by >1.5-fold (Supplemental
Fig. 5A). A comparison between this gene set and genes to
which ERa and themeCBP species had been recruited at 1
h identified;400 genes (Fig. 7; Supplemental PowerPoint
file) that are likely to correspond to primary targets.
Indeed, the large majority of these genes harbor EREs
(red bars below names in Fig. 7; Supplemental PowerPoint
file) and display acetylation at their TSS (blue bars above
names in Fig. 7; Supplemental PowerPoint file). Note that,
in this respect, de novo motif discovery for the chromatin-
binding sites revealed, as expected, EREs for all meCBP
species (data not shown). The other estrogen-regulated
genes are likely to comprise CBP-independent and in-
directly regulated ER target genes. Among the CBP-de-
pendent ER target genes (referred to as ‘‘ER-CBP regulon’’),
Ceschin et al.
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Figure 6. Global analysis reveals meCBP-specific positioning and HAT activity. (A) Venn diagrams showing the number of common
peaks of meCBP species 610 kb around the TSS. (B) Density plots of the sites around the TSS are shown for CBP, ERa, RAC3, H3/4ac,
and the meCBP species. (C) Global distribution of meCBP species. Only sites binding a single meCBP species were considered. (D)
Correlation between global H3/4 acetylation and recruitments of ERa and (me)CBP. The box plot shows the peak populations for loci
that display peaks for H3/4ac only (gray); H3/4ac and ERa (red); H3/4ac, ERa, and CBP (A22) (dark green); H3/4ac, ERa, and CBPR768me2a
(light green); H3/4ac, ERa, and CBPR2151me2a (light blue); and H3/4ac, ERa, and CBPR742me2a (orange). Painted boxes below the X-axis
indicate the presence of signal and half-painted boxes indicate the presence of other CBP species at some of these loci. H3/4 acetylation
is increased statistically significant (P < 0.0001; Mann-Whitney test) at loci containing ERa alone and at those containing ERa together
with (me)CBP. Populations of peaks at loci containing CBPR768me2a (yellow) or CBPR742me2a (orange) exhibit a statistically significant
increase of H3/4 acetylation if compared with the entire population of CBP-positive sites (revealed by the A22 antibody; green) or loci
(blue) occupied by CBPR2151me2a (P < 0.0001; Mann-Whitney test). (E, top panel) Cell extracts from H3396 cells transiently infected with
either empty PLKO lentivirus or PLKO containing shRNAs directed against CBP or CARM1 were subjected to immunoblotting with
anti-CBP and anti-CARM1 antibody 72 h post-infection. TIF1b and actin were used as loading controls for CBP and CARM1,
respectively. (Bottom panels) H3396 infected with shRNAs directed against CBP and CARM1 were subjected to ChIP assays with the
indicated antibodies after 1 h of treatment with E2 or vehicle (EtOH). Bound DNAwas amplified by qPCR with primers specific to TFF1
promoter. Error bars correspond to standard deviations.
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we separated four classes of regulated gene sets: those
recruiting all three species, and three sets that bound CBP
methylated at only a single site. Analysis of these sets
revealed major functional differences. Most notably, the
CBPR768me2a gene set comprised nearly 20% of TFs, while
2% of TFs were found in the CBPR742me2a gene set
(Supplemental Fig. 5B). Moreover, the fraction of down-
regulated genes was significantly higher (50%) when only
Figure 7. Illustration of the ER-meCBP regulon and its functional status 1 h after estrogen treatment. A comprehensive illustration of
the regulon up to 24 h after treatment and of the pathways in which the various ER targets are involved is shown as a Supplemental
PowerPoint file. The regulon was constructed by crossing transcriptomics profiles at 1, 2, 6, and 24 h after estrogen induction (only
genes with >1.5-fold changes of expression were considered) with the ChIP-seq data at 1 h, considering genes in 10 kb vicinity of meCBP
binding sites. The four hubs comprise regulated genes that bind either all three meCBP species simultaneously or only one of the three
species alone. Note that, in the case of triple species binding, it is not possible to distinguish between three separate meCBP molecules
and a single CBP bearing all three methyl tags. Within the regulon, TFs are indicated as well as the regulation status (color-coded), the
presence of histone acetylation in the vicinity of the TSS, and the presence of EREs (codes are specified in the figure). The connectivity
of the various genes in the ER-meCBP regulon was derived from cocitation analysis and is depicted by the color of the gene circle
according to the code given in the figure. This connectivity is illustrated by lines connecting the various genes, and places most of the
TFs in the center of the regulon.
Ceschin et al.
1142 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on August 29, 2017 - Published by genesdev.cshlp.orgDownloaded from 
CBPR742me2a was recruited upon estrogen exposure than
CBPR768me2a (31%). This was particularly obvious at the
6-h time point, when the highest gene regulatory activity
was measured. Genes to which all three species were
recruited comprised 22% of TFs and were generally up-
regulated (87%) by estrogen (Supplemental Fig. 5B–D).
An investigation of the relationships between the genes
of the ER-CBP regulon by cocitation (Genomatix) and
KEGG pathway analysis (DAVID) revealed an intricate
network of temporally regulated ER target genes to which
single or multiple meCBP species are recruited. This
network can be deconvoluted into hubs according to the
binding pattern of meCBP species (displayed as circles in
Fig. 7; Supplemental PowerPoint file) and a central compo-
nent of highly cocited targets that comprise TFs (e.g.,
EGR3, KLF10, GATA3, FLH2, ID1, SMAD1, and MYBL1),
including nuclear receptors (e.g., ER, PGR, RARA, and
NR5A2), cytokines (e.g., TNF and IL13), growth factors or
growth factor receptors (e.g., TGFB3, KITLG, and FGFR),
kinases (e.g., EFNA1, RET, PRKCE, and SGK1), cell cycle
regulators (e.g., CHEK2), or other types of pleiotropic
regulators (e.g., ITPR1, DUSP1, RNF167, SDC2, and
RASGRP1). It is worth noting that factors belonging to
the same gene family were found to involve differential
recruitment of meCBP species. For example, the progester-
one receptor gene associated with CBPR768me2a only, while
all three meCBP species were recruited to the promoter of
the retinoic acid receptor gene. Similary, eight snoRNAs
genes recruited either CBPR768me2a or CBPR742me2a. The
above deconvolution of the ER-CBP regulon reveals appar-
ent subprogramming of the estrogen-induced gene pro-
gram, which is based on the differential recruitment of
methylated CBP species to a particular target site.
Discussion
Numerous studies in model systems have shown that
chromatin acetylation generally precedes transcription
(Cosma 2002) and that formation of a transcription pre-
initiation complex involves recruitment of CBP/p300
chromatin remodeling complexes as a critical early step
(Black et al. 2006). However, one of the questions that has
been very poorly addressed, especially at the genome-wide
level, is how chromatin binding of an incoming signal like
the holo-ER is diversified such that subsets of genes are
coordinately regulated in a gene- and temporally con-
trolled manner, as has been visualized early on in Dro-
sophila (Ashburner et al. 1974). To gain insight into the
early events of signal diversification, we set out to study
the interplay between the different epigenetic enzymes
corecruited by ERa/p160 complexes, CBP, and CARM1,
initially on the prototypic TFF1 target gene and at the
genome-wide scale to reveal the consequences of CARM1-
mediated CBP methylation (Chevillard-Briet et al. 2002).
Our results reveal that CBP methylation is required for
estrogen-dependent recruitment of CBP to ERa target
genes, as knocking down CARM1 resulted in significantly
reduced recruitment of total CBP and also of CBPR2151me2a
to TFF1, paralleling the decreased cellular levels of this
meCBP species; yet, no compensatory chromatin recruit-
ment of CBPR2151non-me was seen despite its increased
cellular levels. Moreover, in contrast to their wild-type
parent, the methylation-deficient CBP mutants were not
efficiently recruited to estrogen target genes, most likely
due to a decreased or impaired binding to the coactivator
RAC3 in vivo. These results suggest that methylated
arginines of CBP may correspond to a docking surface for
factors required to stabilize CBP at target gene chromatin.
Indeed, CBP mutated at R714, R742, and R768 was not
recruited to class II transactivator (CIITA) target sites in
transient ChIP assays (Zika et al. 2005). However, the
development of antibodies recognizing selectively the
corresponding nonmethylated epitopes is required to prove
this hypothesis.
It has been suggested that methylation of p300R2142
destabilizes binding to GRIP1 (YH Lee et al. 2005). No
such function could be attributed to the corresponding
R2151 of CBP. CBPR2151me2a was rather more efficiently
coimmunoprecipitated with endogenous RAC3 than the
general A22 anti-CBP antibody, whereas no signal was
seen when antibodies directed against nonmethylated
CBPR2151 were used (data not shown). The absence of
detectable amounts of CBPR2151non-me and the estrogen-
induced recruitment of its methylated counterpart to
cognate promoters support the notion that methylation
of R2151 enhances or is required for RAC3/p160 interac-
tion; this notion is fully supported by a decreased/impaired
RAC3 binding of the corresponding R to K CBP mutants.
Whether methylation of the p160 interaction domains of
CBP has a different function than for p300 remains to be
established, as well as the role of CBPR2151non-me.
Comparative global ChIP-seq profiling of CBP species,
ERa, RAC3, polymerase II, and global H3K18 acetylation
revealed an astounding complexity of estrogen-induced
events in this H3396 breast cancer cell line model, as
visualized by ChordCharts. While the majority of pro-
totypic estrogen target genes such as TFF1, CTSD, and
GREB1 shows the ‘‘classical’’ recruitment mode of ERa,
RAC3, CBP, and meCBP species in a similar hormone-
dependent manner with varying amounts of gene-specific
binding in a hormonally naivemedium, the global analysis
reveals major differences for each of these factors. Indeed,
while the estrogen-inducible genes EBAG9 and CTBP1
bind apo-ERa (and polymerase II) and recruit additional
receptors in a ligand-dependent manner, the amounts of
recruited CBP, meCBP, CARM1, and p300 are negligible
compared with other genes despite a strong peak of H3/4
acetylation; these genes are likely to operate in a CBP/
p300-independent manner by engaging a distinct HAT.
RAC3-free CBP-recruiting estrogen target genes may use
the p160 homologs SRC1 and/or TIF2/GRIP1, supporting
gene selectivity of p160s. Sites devoid of ERa but occupied
by RAC3 are indicative of ERb or other RAC3-using TFs
targeting this locus.
An important result of this study is that CBP methyl-
ation by CARM1 (1) is a gene-specific feature and (2)
increases local acetylation in the presence of CBPR742me2a
or CBPR768me2a but not of CBPR2151me2a, as most if not all
CBP is methylated at this site. Indeed, ChIP-qPCR-based
scatter plots of genes selected from the comparative
Methylation regulates CBP binding to chromatin
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ChIP-seq profiles confirmed that there is a large variation
in the amount of a particular meCBP species recruited by
estrogen to a given target. Similarly, also the relative
abundance of CBP and the p160 RAC3 can vary in a gene-
specific manner. In addition to altered HAT activity, it is
tempting to speculate that methylation may provide
novel surfaces for interaction with other factors or for
stabilization of assembled complexes. A functional di-
versity of meCBP species is supported by the observations
that CBP HAT activity is differently affected by methyl-
ation at R742, R768, or R2151, and that CBPR742me2a/
CBPR768me2a binding to promoters increases its probabil-
ity of being acetylated. The observed cross-talk for
methylation at R742 and R2151 suggests coregulation
of CARM1 activity at these sites that may correspond to
a composite signal recognized by (a) specific ‘‘reader(s).’’
The variation in both the recruitment of CBP relative to
RAC3 and gene-specific recruitment of a particular (set
of) meCBP species allows for a large heterogeneity, which
could account for certain features in the timing and
response intensity of a given target gene, thereby setting
up an orchestrated and diversified response initiated by
a single small molecular chemical signal.
Crossing of ChIP-seq and transcriptomics profiling,
together with the corresponding gene annotation, turned
out to be a powerful method to deconvolute the estrogen-
induced gene program. Among the target genes that
involve meCBP recruitment (the ER-CBP gene regulon),
we observed an astounding diversification of an intricate
estrogen-regulated gene network in H3396 cells. Func-
tional diversification involved, for example, the fraction
of TF genes to which a given meCBP species bound; the
majority of TF targets bound CBPR768me2a or all three
meCBP species, while CBPR742me2a recruitment involves
hardly any TF genes. Similarly, CBPR742me2a is recruited
as frequently to estrogen down-regulated genes as to up-
regulated genes, while the presence of all three methyl-
ations is highly predictive for transcription activation.
The observation of a cross-talk between the methylation
sites supports the view of a regulated ‘‘writing’’ of these
marks. While, at present, we have no technical approach
to decipher the complete set of factors bound to a target
site at a given point in time, we believe that (some of) the
factors—including epigenetic and transcription regula-
tory marks and machineries—that make up the identity
of a given chromatin site will direct the substrate selec-
tivity of CARM1. In turn, the set of meHATs at a given
site is likely to contribute to signaling, together with the
other factors, to generate the ultimate temporally con-
trolled transcriptional readout. It is tempting to speculate
that CARM1-methylated CBP residues correspond to
docking sites for ‘‘readers,’’ which altogether generate
the observed transcriptional input at a given target site.
Cocitation analysis reveals a tight connection between
the meCBP hubs in which TFs play, as expected, a dom-
inant role. However, similarly central are cytokines,
growth factors or growth factor receptors, kinases, and
cell cycle regulators. Including pathway annotation and
kinetics of transcription activation (Supplemental Power-
Point file) provides a comprehensive view of how ER and
(methylated) coregulator recruitment ultimately generates
a temporally controlled transcription response that can be
deconvoluted into multiple hubs of genes. A multidimen-
sional analysis of TF and coregulator binding, histone
modification, and polymerase recruitment/activity, together
with the corresponding (nascent) transcription profiling,
including noncoding RNAs, will ultimately reveal the de-
tails of the cognate gene program and its key elements that
may be altered in pathology.
CBP displays features of a tumor suppressor (for re-
view, see Iyer et al. 2004), and a high frequency of human
follicular lymphoma, diffuse large B-cell lymphoma, and
relapsed lymphoblastic leukemias display deletion/mu-
tation of CREBBP (Mullighan et al. 2011; Pasqualucci
et al. 2011). As also CARM1 may be deregulated in
cancer (Hong et al. 2004), it is possible that aberrant
methylation of CBP may be observed in cancer, either as
a marker or even linked to the transformation process.
Indeed, our preliminary tissue microarray analysis re-
veals a deregulation of the epi-enzyme cross-talk in
several types of cancers, and suggests a link between
abnormal CBP methylation and disease progression.
Given the impact of CARM1 and of CBP in key growth
regulatory circuits, and the role of CBP in cell differen-
tiation (Kawasaki et al. 1998), it will be interesting to
assess the relevance of site-selective CBP aberrant ex-
pression/mislocalization in cancer.
Materials and methods
Cell lines, reagents, and antibodies
H3396 cells were maintained in RPMI 1640 supplemented with
10 mM HEPES, 10% fetal bovine serum (FBS), and antibiotics.
Clone 3 (CARM1/) and clone 13 (CARM1+/+) of MEFs (Yadav
et al. 2003), a gift from Dr. M. Bedford, were cultured in DMEM
supplemented with antibiotics and 10% fetal calf serum. ERa
(HC20), CBP (A22), p300 (N15), HA (12CA5), and RAC3 (M397)
antibodies were from Santa Cruz Biotechnology; anti-acetylCBP
was from Cell Signaling; ChIP-grade antibodies against H3K14ac
(07-353) was from Millipore, and H3K18ac (ab1191) was from
Abcam. FuGENE 6 transfection reagent was purchased from
Roche, and b-estradiol was purchased from Sigma Chemicals.
Generation and purification of antibodies
Peptides used for immunization of rabbits encompass the arginine
residue of interest either in the unmodified form or asymmetrically
dimethylate (Supplemental Material). All peptides were coupled to
ovalbumin, validated by SDS-PAGE, and injected into rabbits.
Samples of the rabbit serum drawn before immunization (preim-
mune control) and at different time points after immunization and
boost were tested by Western blotting using nonmethylated or in
vitro methylated CBP fragments. Monospecific polyclonal anti-
bodies were obtained by differential dual affinity chromatography
using sulfolink resins prepared according to the manufacturer’s
protocol (Pierce). For example, anti-CBPR768me2a antibodies were
obtained by positive selection from serum passed over a first
column containing the immobilized ISPS(Rme2a)MPQPC peptide.
Serum was applied by gravity flow, washed with Tris-buffered
saline, and eluted with 0.1 M glycine-HCl (pH 2.5), and the eluate
was neutralized with 1 M Tris-HCl (pH 8.5). Antibodies cross-
reactingwith the cognate nonmethylated peptidewere removed by
Ceschin et al.
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negative selection on a second column containing the immobilized
ISPSRMPQPC peptide. Antibody titer and specificity were de-
termined by ELISA using not only methyl-arginine and non-
methyl-arginine peptides but also peptides containing the other
potential methylation sites (Supplemental Material). Antibodies
showing sufficient selectivity in ELISA were selected and used in
this study.
Plasmids and recombinant proteins
pGEXCBP (amino acids 1869–2441) was a kind gift from A. Harel-
Bellan and pGEX CBP (amino acids 685–774) was described
previously (Chevillard-Briet et al. 2002). GST fusion proteins were
expressed in BL21 bacteria as explained before (Vandel et al. 2001).
pRSETB CBP (amino acids 685–774) was made by digestion of
pGEX CBP (amino acids 685–774) by HindIII/BamH1 and intro-
duction into pRSETB cut by HindIII/BglII. pCMV-HA-CBP and
pCMV-HA-CBPDHAT were provided by A. Harel-Bellan. pCMV-
HA-CBPR714K, pCMV-HA-CBPR742K, pCMV-HA-CBPR768K, pCMV-
HA-CBPR600,625K, and pCMV-HA-CBPR2104,2151K were obtained by
in vitro site-directed mutagenesis with GeneEditor (Promega) and
were reintroduced into pCMV-HA-CBP cut by AflII–BglII or Xba1
(R2104/2151K mutant). Fragments containing the single mutants
were subcloned from pCMV-HA-CBPR714K, pCMV-HA-CBPR742K,
pCMV-HA-CBP768K, and pCMV-HA-CBP2104K/2151K into pBABE-
HA-CBP hygro with BstBI to generate the corresponding pBABE-
HA-CBPmutant vectors. The pBabe-HA-CBP vectors were used to
generate stable H3396 cell lines expressing HA-CBP wild type
and the methylation-deficient mutants. shRNA against hu-
man CARM1 and CBP were designed from Sigma-Aldrich and
were cloned into lentiviral vector pLKO.1-puro (Addgene).
Immunoprecipitation, Western blotting, RT–PCR, siRNA,
and shRNA tranfections
Immunoprecipitation and co-IP experiments were performed as
described (Fauquier et al. 2008). For RT–PCR, total RNA was
extracted from cells using GenElute RNA extraction kit (Sigma).
Two micrograms of total RNA were reverse-transcribed using
AMV-RTase (Roche) with oligo(dT) (New England Biolabs) as
primers for 1 h at 42°C according to standard procedures. cDNAs
were then diluted 10-fold and analyzed by real-time PCR using
the Roche LC480 LightCycler device with sequence-specific
primers and SYBR Green QPCR MasterMix (Qiagen). Primers
for amplification of target genes are listed in the Supplemental
Material. All qPCR values were normalized relative to 36B4
mRNA, and standard deviations were calculated.
For siRNA transfection, 53 106 cells were electroporated with
siRNA using the Cell Line Nucleofector kit (Amaxa Biosystem)
according to the manufacturer’s instructions. siRNA-mediated
knockdown efficiency was assessed by qPCR and immunoblotting.
All experiments were performed 48 h after nucleofection. siRNA
sequences are given in the Supplemental Material. The control
siRNA used was the Allstar Negative Control siRNA fromQiagen.
For shRNA transfections and virus production, pLKO.1 lenti-
viral vector containing or not containing shRNAs directed
against CBP and CARM1 was transfected with the packaging
plasmids pLP1, pLP2, and pLP/VSVG (Invitrogen) using FuGENE
HD Transfection Reagent (Roche) in HEK293Tcells according to
the manufacturer’s instructions. After 48 h, the supernatant of
HEK293T was used to infect H3396 cells, and knockdown
efficiency was monitored 72 h later by Western blotting.
Generation of stable H3396 cell lines
The retroviral plasmids expressing pBABE-HA-CBP and the
mutants were transfected in HEK293T cells along with pCLII
Ampho helper plasmid (Imgenex) with FuGENE6 transfection
reagent (Roche). After 48 h, the medium was collected and
filtered through a 0.4-mm filter before being used to infect
H3396 cells. Cells were then treated with hygromycin B and
expanded. Stable integration and expression of the plasmids were
monitored by qPCR and immunoblotting with an HA antibody.
Methylation and acetylation assays
In vitro methylation assays of CBP fragments (GSTor His fusion
proteins of CBP) with recombinant CARM1 have been described
(Chevillard-Briet et al. 2002). Acetyltransferase activity of CBP
was assessed after immunoprecipitation in CARM1+/+ and
CARM1/ MEFs. Immunoprecipitations were performed with
either anti-CBP-A22 antibody or an irrelevant antibody. Immu-
noprecipitations were mixed with 3 mg of histone H3 peptide
(residues 1–22) and 0.3 mM [3H]-acetyl-coenzyme A (GE Health-
care). Reactions were performed for 45 min at 30°C in 50 mM
Tris (pH 8.0), 150mMNaCl, 5mMEDTA, and 0.5%NP40 before
being spotted on P81 (Whatman). Filters were rinsed twice for 1 h
with 50 mM Na2CO3 (pH 9.0), and histone H3 acetylation was
determined by liquid scintillation counting.
ChIP, ChIP-seq, re-ChIP, and peptide competitions
ChIP assays were performed according to standard protocols, and
the conditions used for the various antibodies are detailed in the
Supplemental Material. Quantitative real-time PCRs of bound
promoters were performed with 2 mL of DNA, sequence-specific
primers, and the SYBR Green QPCR MasterMix (Qiagen). The
primer pairs used are listed in the Supplemental Material. For re-
ChIPs, immunocomplexes were eluted in 10 mM DTT for 30
min at 37°C. The eluate was diluted 50 times in ChIP dilution
buffer for reimmunoprecipitation with a second antibody. For
peptide competition experiments, antibodies were preincubated
with a 100-fold molar excess of peptide for 1 h at 4°C. The
antibody–peptide mixture was then added to the soluble chro-
matin followed by ChIP. ChIP-seq and the data analysis pipeline
are described in the Supplemental Material.
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